A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.

Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T, Brambilla P, Liberatore G, Guaschino C, Romeo M, et al.